




Complete Hematological Response




Molecular Response




Adverse events leading to discontinuation




JAK2V617F allele burden



Thrombotic Event



Number of phlebotomies per patient per year



Supplementary Figure 1 Funnel plots assessing publication bias for outcomes.

Supplementary Table 1 GRADE assessment of evidence certainty for outcomes

Name of outcome	No. of studies	Study design	Risk of bias	Inconsistency	Imprecision	Indirectness	Effect size (OR/MD + CI)	Certainty of evidence
CHR	5	RCTs	Not serious (majority low risk)	Serious (I ² =76%, reduced to 48.3% upon removal of Glissinger 2020(P))	Not serious (narrow CI: 1.18-3.88)	Not serious	OR=2.14 (95%CI: 1.18-3.88)	Moderate
Molecular response	4	RCTs	Not serious (majority low risk)	Serious (I ² =93%, reduced to 12% upon removal of Glissinger	Serious (wide CI: 0.99-19.38, close to 1)	Not serious	OR=4.37 (95%CI: 0.99-19.38)	Low

2020(P))

Adverse effects leading to discontinuation	5	RCTs	Not serious (majority low risk)	Not serious (I ² =0%, no heterogeneity)	Not serious (narrow CI: 1.90-7.97)	Not serious	OR=3.89 (95%CI: 1.90-7.97)	High
JAK2V617F allele burden	4	RCTs	Not serious (majority low risk)	Serious (I ² =90%, reduced to 72% upon removal of Glissinger 2020(P))	Serious (wide CI: -21.12 to 6.20, crossing 0)	Not serious	MD=-7.46 (95%CI: -21.12 to 6.20)	Low
Thrombotic events	4	RCTs	Not serious (majority low risk)	Not serious (I ² =0%, no heterogeneity)	Serious (wide CI: 0.45-1.90, crossing 1)	Not serious	OR=0.93 (95%CI: 0.45-1.90)	Moderate
Number of phlebotomies	2	RCTs	Not serious	Not serious (I ² =0%, no heterogeneity)	Not serious (narrow CI: 1.90-7.97)	Not serious	MD=-1.52 (95%CI: 1.90-7.97)	High

per patient per	(majority heterogeneity)	-2.37 to -0.67)	-2.37	to
year	low risk)		-0.67)	

RCT: Randomized controlled trial; 95%CI: 95% confidence interval; P: PROUD-PV phase; C: CONTINUATION-PV phase.